Pacific Edge’s American dream

Pacific Edge’s American dream
The US Affordable Care Act can be tricky to navigate. (Image: Getty)
Paul McBeth
Pacific Edge has long wanted to crack the United States market, which it has seen for a long time as validating the hundreds of millions spent in developing its Cxbladder non-invasive cancer detection tool. More than 20 years since listing, after it was spun out of University of Otago research, the company has raised $297.23 million selling shares and convertible preference shares and as people exercised options to fund accumulated losses of $216.8m and counting. That’s not going to change any time soon after the company crashed...

More Markets

NZ sharemarket up 0.5% ahead of long weekend
Markets Market Close

NZ sharemarket up 0.5% ahead of long weekend

Pacific Edge's share price fell 7.32%.

Tom Raynel 24 Apr 2025
Pacific Edge suffers another setback in US
Markets

Pacific Edge suffers another setback in US

Shares in cancer diagnostics company Pacific Edge are down 2.44% to $0.120 after another setback in the US market.The US District Court for the Middle District of Pennsylvania has determined that it does not have jurisdiction to review a Local Coverage Determination (LCD) that co...

Staff reporters 24 Apr 2025
Listed retailers stand to gain from Trump tariffs:  Forsyth Barr
Retail

Listed retailers stand to gain from Trump tariffs: Forsyth Barr

Forsyth Barr lifted its KMD Brands target price by 10.4% after Trump tariff walkbacks.

Gregor Thompson 24 Apr 2025
NZ sharemarket rises as Trump backs down
Markets Market Close

NZ sharemarket rises as Trump backs down

The S&P/NZX 50 Index closed up 1.01% or 119.78 points.

Tom Raynel 23 Apr 2025